[go: up one dir, main page]

WO2000068385A3 - Novel nucleic acids and proteins with growth hormone activity - Google Patents

Novel nucleic acids and proteins with growth hormone activity Download PDF

Info

Publication number
WO2000068385A3
WO2000068385A3 PCT/US2000/013175 US0013175W WO0068385A3 WO 2000068385 A3 WO2000068385 A3 WO 2000068385A3 US 0013175 W US0013175 W US 0013175W WO 0068385 A3 WO0068385 A3 WO 0068385A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
growth hormone
nucleic acids
hormone activity
novel nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013175
Other languages
French (fr)
Other versions
WO2000068385A9 (en
WO2000068385A2 (en
Inventor
Anton Filikov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to AU51329/00A priority Critical patent/AU5132900A/en
Priority to EP00935944A priority patent/EP1177297A2/en
Priority to CA002372871A priority patent/CA2372871A1/en
Priority to JP2000616351A priority patent/JP2002543788A/en
Publication of WO2000068385A2 publication Critical patent/WO2000068385A2/en
Publication of WO2000068385A3 publication Critical patent/WO2000068385A3/en
Anticipated expiration legal-status Critical
Publication of WO2000068385A9 publication Critical patent/WO2000068385A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

The invention relates to novel growth hormone activity (GHA) proteins and nucleic acids. The invention further relates to the use of the GHA proteins in the treatment of growth hormone related disorders.
PCT/US2000/013175 1999-05-12 2000-05-12 Novel nucleic acids and proteins with growth hormone activity Ceased WO2000068385A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU51329/00A AU5132900A (en) 1999-05-12 2000-05-12 Novel nucleic acids and proteins with growth hormone activity
EP00935944A EP1177297A2 (en) 1999-05-12 2000-05-12 Novel nucleic acids and proteins with growth hormone activity
CA002372871A CA2372871A1 (en) 1999-05-12 2000-05-12 Novel nucleic acids and proteins with growth hormone activity
JP2000616351A JP2002543788A (en) 1999-05-12 2000-05-12 Novel nucleic acids and proteins with growth hormone activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13378499P 1999-05-12 1999-05-12
US60/133,784 1999-05-12

Publications (3)

Publication Number Publication Date
WO2000068385A2 WO2000068385A2 (en) 2000-11-16
WO2000068385A3 true WO2000068385A3 (en) 2001-02-15
WO2000068385A9 WO2000068385A9 (en) 2002-04-18

Family

ID=22460287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013175 Ceased WO2000068385A2 (en) 1999-05-12 2000-05-12 Novel nucleic acids and proteins with growth hormone activity

Country Status (5)

Country Link
EP (1) EP1177297A2 (en)
JP (1) JP2002543788A (en)
AU (1) AU5132900A (en)
CA (1) CA2372871A1 (en)
WO (1) WO2000068385A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515178A (en) * 2001-11-23 2004-09-24 Agres Ltd Modulating prolactin receptors to affect a physiological response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011178A1 (en) * 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
WO1998047089A1 (en) * 1997-04-11 1998-10-22 California Institute Of Technology Apparatus and method for automated protein design

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011178A1 (en) * 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
WO1998047089A1 (en) * 1997-04-11 1998-10-22 California Institute Of Technology Apparatus and method for automated protein design

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ATWELL SHANE ET AL: "Structural plasticity in a remodeled protein-protein interface.", SCIENCE (WASHINGTON D C), vol. 278, no. 5340, 7 November 1997 (1997-11-07), pages 1125 - 1128, XP002150985, ISSN: 0036-8075 *
DAHIYAT B I ET AL: "PROTEIN DESIGN AUTOMATION", PROTEIN SCIENCE, vol. 5, no. 5, May 1996 (1996-05-01), pages 895 - 903, XP002073372, ISSN: 0961-8368 *
LOWMAN HENRY B ET AL: "Affinity maturation of human growth hormone by monovalent phage display.", JOURNAL OF MOLECULAR BIOLOGY, vol. 234, no. 3, 1993, pages 564 - 578, XP000953072, ISSN: 0022-2836 *
ULTSCH MARK H ET AL: "The crystal structure of affinity-matured human growth hormone at 2 A resolution.", JOURNAL OF MOLECULAR BIOLOGY, vol. 236, no. 1, 1994, pages 286 - 299, XP000953071, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
EP1177297A2 (en) 2002-02-06
JP2002543788A (en) 2002-12-24
WO2000068385A9 (en) 2002-04-18
AU5132900A (en) 2000-11-21
WO2000068385A2 (en) 2000-11-16
CA2372871A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
WO2000068387A3 (en) Nucleic acids and proteins with interferon-beta activity
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
EP2292771A3 (en) Sense mRNA therapy
AU6968898A (en) Antisense oligonucleotide compositions and methods for the modulation of activating protein
PL339463A1 (en) April - novel protein of growth promoting action
AU646231B2 (en) Recombinant DNA constructs of tospoviruses and their use in plants
AU2572499A (en) Human hairless gene, protein and uses thereof
AU2289601A (en) The use of procyanidins in the modulation of cytokine gene expression and protein secretion
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
WO2000069901A3 (en) Proteins with insulin-like activity useful in the treatment of diabetes
AU1752701A (en) Stanniocalcin proteins and nucleic acids and methods based thereon
AU2002221755A1 (en) Nucleotide and polypeptide sequence of human lysosomal acid lipase
AU3982497A (en) Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner
AU2001234544A1 (en) Novel human protein kinases and protein kinase-like enzymes
WO2002004521A3 (en) Proteins with integrin-like activity
AU1867297A (en) Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders
WO2000068385A3 (en) Novel nucleic acids and proteins with growth hormone activity
AU7846000A (en) Novel human lipase proteins, nucleic acids encoding them, and uses of both of these
AU3333399A (en) Nucleotide sequence expressing human fatty acid transport protein and corresponding aminoacid sequence. use for the regulation of fatty acids metabolism
IL149506A0 (en) Human heparanase-related polypeptide and nucleic acid
AU1855001A (en) A new member of the pak protein family, nucleic acids and methods related to thesame
WO2000068384A3 (en) NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
AU3996799A (en) Alpha amino acid composition and method for the treatment of skin
AU6692300A (en) Tankyrase homolog protein (thp), nucleic acids, and methods related to the same
GB9509461D0 (en) DNA molecules and constructs and their use in the treatment of mastitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 51329/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2372871

Country of ref document: CA

Ref country code: CA

Ref document number: 2372871

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616351

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000935944

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000935944

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 75, CLAIMS, REPLACED BY A NEW PAGE 75; PAGES 1/17-17/17, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000935944

Country of ref document: EP